Gujral, SAgarwal, AGota, VNair, RGupta, SPai, S KSanger, MShet, TSubramanian, P GMuckaden, MLaskar, S2008-07-302009-05-292008-07-302009-05-292008-07-30Gujral S, Agarwal A, Gota V, Nair R, Gupta S, Pai SK, Sanger M, Shet T, Subramanian PG, Muckaden M, Laskar S. A clinicopathologic study of mantle cell lymphoma in a single center study in India. Indian Journal of Pathology & Microbiology. 2008 Jul-Sep; 51(3): 315-22http://imsear.searo.who.int/handle/123456789/72871We present clinical features, histopathology and results of treatment in cases of mantle cell lymphoma (MCL) at our hospital. We had 93 cases (2.1%) of MCL out of total 4301 cases of non-Hodgkin's lymphoma (NHL) in a 4-year period. It included 68 cases (1.7%) of MCL from 3987 cases of NHL diagnosed on histopathology. Remaining 25 cases (7.9%) diagnosed solely on peripheral blood examination were excluded. Thirty-six (85%) patients had advanced-stage disease. Sixty-three were nodal and five were extranodal (all gastrointestinal tract). Common patterns were diffuse (64%), nodular (25%) and mantle zone type (11%). Sixty-two cases had lymphocytic while six had blastic morphology (all nodal). Tumor cells expressed CD20 (100%), CD43 (94%), CD5 (89%) and cyclin D1 (85%). Bone marrow was involved in 25 (59%) cases. Thirty-two patients could be treated. Median recurrence-free survival was 22.23 months. Diffuse pattern of nodal involvement had a lower overall survival.engAdultAgedAntigens, CD20 --biosynthesisAntigens, CD43 --biosynthesisAntigens, CD5 --biosynthesisAntineoplastic Agents --therapeutic useBone Marrow --pathologyCyclin D1 --biosynthesisFemaleGastrointestinal Tract --pathologyHospitalsHumansIndiaLymphoma, Mantle-Cell --drug therapyMaleMiddle AgedSurvival AnalysisJournal Article